Human low-grade gliomas represent a population of brain tumors that remain a therapeutic challenge. Preclinical evaluation of agents, to test their preventive or therapeutic efficacy in these tumors, requires the use of animal models. Spontaneous gliomas develop in models of chemically induced carcinogenesis, such as in the transplacental N-ethyl-N-nitrosourea (ENU) rat model. However, without the ability to detect initial tumor formation, multiplicity or to measure growth rates, it is difficult to test compounds for their interventional or preventional capabilities. In this study Fisher-334 rats, treated transplacentally with ENU, underwent magnetic resonance imaging (MRI) examination in order to evaluate this approach for detection of tumor formation and growth. ENU-induced intracranial cerebral tumors were first observable in T2-weighted images beginning at 4 months of age and grew with a mean doubling time of 0.487 ± 0.112 months. These tumors were found histologically to be predominately mixed gliomas. Two therapeutic interventions were evaluated using MRI, vitamin A (all-trans retinol palmitate, RP), as a chemopreventative agent and the anti-angiogenic drug SU-5416. RP was found to significantly delay the time to first tumor observation by one month (P = 0.05). No differences in rates of tumor formation or growth rates were observed between control and RP-treated groups. MRI studies of rats treated with SU-5416 resulted in reduction in tumor growth rates compared to matched controls. These results show that MRI can be used to provide novel information relating to the therapeutic efficacy of agents against the ENU-induced tumor model.
Introduction
Gliomas comprise the majority of the primary brain tumors diagnosed annually in the United States [1, 2] . Of these tumors, low-grade gliomas are relatively common, with low-grade astrocytic tumors alone comprising as much as 15-32% of surgically treated brain tumor [3, 4] . These tumors are characterized as having a benign histologic picture, indolent growth, and prolonged survival, but their biologic behavior is unpredictable [5] [6] [7] [8] . Some lesions appear curable, but low-grade tumors have been shown to have a propensity to develop anaplastic features [5, 7, 9, 10] . This progression is thought to be due to the genetic instability of the low-grade gliomas, which allows additional genetic deletions, amplifications, and mutational events to occur [11] . This progression or change in tumor grade, can take the life of the patient sometimes decades after initial diagnosis [6, 12] .
Currently, therapies for low-grade gliomas include observation, resection, radiation, and chemotherapy. Due to the infiltrative nature of gliomas, surgery is rarely curative. In some locations, radical surgery with newer image-guided techniques and functional mapping offers the prospect of prolonged survival by allowing better and more complete surgical excisions. There is controversy about the role of radiation therapy in the management of low-grade gliomas. Some centers have reported no benefit in length or quality of life, while others have detected a small benefit to radiation [13] [14] [15] .
Chemotherapy regimens, found to have benefit in highgrade gliomas, are currently in trial for low-grade gliomas. Although there is increasing evidence that combination-agent chemotherapy such as carboplatin and vincristine can delay progression of low grade gliomas, long-term outcome data (10-20 year) are not available [16] .
The current lack of curative therapeutic options for treatment of low-grade gliomas indicates that alternative therapies need to be considered. However, the scarcity of suitably characterized low-grade glioma models for preclinical testing makes the development of new therapies more difficult. Unfortunately, human low-grade gliomas have not been established in culture, nor is there an in vitro model of progression from low-grade to high-grade glioma. Thus, testing of preventative or interventional therapies targeting glial tumor progression currently requires the additional development of in vivo animal models.
One potential model for low-grade gliomas is the induction of rat brain tumors with chemical carcinogens. These are reproducible models that have been utilized for over 30 years. However, wide variations in tumor type, location, size, and growth kinetics exemplify the complexity of these brain tumor models. Their main strength however, has been the spontaneous nature of the induced tumors exhibiting the characteristics of progression over time from small early neoplastic proliferations, evolving into large malignant neoplasms. The offspring of rats given a single intravenous dose of N-ethyl-N-nitrosourea (ENU) later than the 13th day of gestation or during early postnatal development, develop malignant neuroectodermal tumors of the central and peripheral nervous systems [17, 18] . This tumor incidence approaches 100% in many rat strains [19, 20] . The carcinogenic effect is presumably due to the alkylation of DNA by ENU, which occurs rapidly due to the short half-life of the compound. Once completed, the neoplastic transformation remains indolent until a much later time. In this model, early neoplastic proliferation is followed by microtumors and finally visible tumors develop with increasing signs of progression to higher grades of malignancy as indicated by increased mitoses, vascularization, and necrosis. The brain tumors induced by this carcinogen are reported to be primarily astrocytomas, oligodendrogliomas, mixed gliomas, ependymomas, and/or medulloblastomas [21] [22] [23] [24] [25] . However, this may be somewhat dependent on the strain of rat. Several recent reports have analyzed the pathology of transplacentally ENU-induced tumors. Zook et al., found that mixed gliomas grew larger, had a shorter latency, and were significantly more malignant than were other gliomas [26] . Mandeville et al., [27] found that 5 mg/kg of ENU was able to induce from 30-46% glial tumors in Fisher-344 rat offspring. Glial tumors (mixed gliomas and oligodendrogliomas) were the most frequent type of tumors observed. Mixed glial tumors were usually quite large and characterized by a mixture of oligodendroglial cells and astrocytes.
There are a limited number of reports testing agents for their preventive or therapeutic efficacy utilizing chemically induced models of CNS carcinogenesis. These studies have usually been designed as survival studies either with or without interim sacrifices to examine tumor incidence. Alexandrov's group in Russia has used the ENU transplacental carcinogenesis model to examine the preventative or interventional effects of a variety of compounds [28] [29] [30] [31] . They have examined the vitamins; retinol acetate, alphatocopherol acetate and thiamine chloride; the antioxidant sodium selenite; and an inhibitor of polyamine biosynthesis, alpha-difluoromethylornithine (DMFO). DMFO exerted a slight inhibitory effect on tumor incidence, decreased the total CNS tumor multiplicity and the multiplicity of peripheral nervous system tumors. It also prolonged survival time. Retinol, tocopherol, thiamine, and selenite did not influence the development of transplacentally induced tumors [28] . However, all these studies have been hampered by the inability to detect initial tumor formation, multiplicity, and growth of the resulting tumors, in addition to survival of individual animals. The large variation in the time to occurrence and location of the resulting occult tumors has been a tremendous limitation of this model.
Non-invasive MR imaging has demonstrated the capability to perform repeated measurement of tumors derived from orthotopically implanted cell lines and to measure changes in growth rates caused by therapy [32] . Additionally, ENU-induced tumors have been reported as imagable by magnetic resonanace imaging (MRI) [33] [34] [35] [36] . To date, no study has reported the effect of any therapy on chemically induced brain tumors true incidence or growth rates. We, therefore, investigated the capability of repeated MRI measurements to obtain a more accurate determination of the incidence, number and growth rate of tumors in ENU-treated animals. We chose to test two different therapies based upon their different modes of action. We had previously found vitamin A to increase survival in ENU-treated animals fed a diet with increased vitamin A [37] . Statistical analysis suggested that the mechanism of action was a delay in time to tumor formation, a chemopreventative action. Tumor growth is also dependent upon blood supply. Vascular endothelial growth factor (VEGF), by inducing angiogenesis, has been implicated as a major paracrine mediator of glioma development by stimulation of angiogenesis [38] [39] [40] . Inhibition of VEGF receptor 2 (FLK-1/KDR) tyrosine kinase activity has been shown to effectively block angiogenesis and tumor growth of gliomas implanted in rat dorsal skin chambers [41] . We, therefore, examined the effect of SU-5416, a small molecule inhibitor of the VEGF receptor FLK-1, as an interventional therapy to block the growth of small ENU-induced tumors.
Materials and methods

Chemical induction of brain tumors
As in our previous experiment, tumors were induced by transplacental exposure [37] . Timed-pregnant Fisher-334 dams were injected via the lateral tail vein on the 21st day of gestation with 50 mg/kg of a 0.1 M solution of ENU (Sigma, St Louis, MO) dissolved in citric acid: disodium phosphate buffer (pH 6.0) immediately prior to injection. Due to the limited diameter of the head coil used in the MRI scanner, we wanted to ensure that the animal's head could be imaged at one year of age. The Fisher-344 rat strain was chosen as this strain produces small sized animals known to be susceptible to ENU tumor induction [20, 26, 27] . Second, the animals were exposed to ENU on day 21 of pregnancy, a time shown to cause the greatest number of brain tumors in their offspring [42] . The offspring were delivered naturally, were whelped by their natural mothers, and weaned at 21 days of age.
Retinol palmitate dietary treatment
All pups (26) from three dams were randomly assigned to control (ENU exposed) or all-trans retinol palmitate (RP) treated ENU-exposed groups (8 females, 5 males; 13 animals/group). All animals were housed in groups based on sex and treatment groups, and had access to food and water ad libitum. RP-treated animals received standard chow supplemented with 150,000 IU vitamin A palmitate/kg (Sigma, St Louis, MO) as previously described [37, 43] . This was accomplished by stirring standard chow (Purina 5001) in an ethanol solution of RP for 1.5 h in the dark, during which time most of the ethanol evaporates. Although no direct measurement of vitamin A status of the animals was made, our previous experiment had shown that 150,000 IU of dietary vitamin A caused a change in survival in rats. Historically, this concentration has been utilized to study the effect of vitamin A on wound healing in rats, including local tumor irradiation or cyclophosphamide treatment [43] . This concentration is approximately 10 times the basal dietary concentration of vitamin A found in normal rat chow (approximately 15,000 IU vitamin A and 6.4 mg β-carotene/kg) which exceeds the recommended minimum daily allowance for rodents. Animals on both diets gained weight corresponding to the normal growth curves for their strain. ENU-induced dams and ENU-control offspring were fed standard lab rodent chow treated with ethanol alone (ENU control animals). Food was replaced twice a week. It was prepared at one-week intervals and stored at 4
• C. Animals with no reported death or autopsy, were censored after the last known time of imaging or observation. This censoring affected survival analysis and percentage of animals with a given tumor histology.
Magnetic resonance imaging
Monthly MRI images were obtained beginning at 2 months of age. Animals were imaged every month (months 2-8) for the purpose of determining the incidence, number, and growth rate of each tumor. Animals were anesthetized with 2% isoflurane in air during the imaging sessions. All in vivo MRI experiments were performed on a Varian system equipped with a 7.0 Tesla, 18.3-cm horizontal bore magnet (300 MHz proton frequency). Each MRI session acquired T2-weighted images through the rat brain, which were produced using the following parameters: TR/TE = 3,500/60, FOV = 30 × 30 mm using a 256 × 128 matrix; slice thickness = 0.5 mm; number of slices = 50; slice separation = 0.0 mm by interleaving two sets of 25 slices. The 0.5-mm interleaved sections routinely allowed detection of tumors as small as 1 mm in diameter. We limited this experiment to the imaging of intracranial cerebral tumors. This eliminated leptominengeal tumors, schwannomas, and several other tumor types. The most relevant tumor diagnosis for the remaining tumors was oligodendrogliomas, astrocytomas, mixed gliomas, or ependymomas. Tumor volume determination of the first tumor formed from serial image slices was accomplished as described [32] . Tumor volumes measured excluded any cyst volume present.
Histologic evaluation
Brains and spinal cords were dissected free from the cranium or spine and fixed by immersion fixation in 10% buffered formalin. Spinal cord tumors were visually determined with the aid of a dissecting microscope. To evaluate the histopathology of each MRI lesion, a 5-µm thick paraffin-embedded section of the brain corresponding to the MRI imaged lesion was stained with hematoxylin and eosin. All paraffin sections were examined by a neuropathologist (MB) blinded as to the group and age of the lesion. Each neoplasm was diagnosed and graded according to the criteria described by Zook et al. [26] . In the case of heterogeneous tumors, tumors were graded at the highest grade observed.
Additionally, paraffin sections of the cerebral tumors used in the measurement of tumor volume (first intraparenchymal tumor formed in the cerebrum of the rat) were immunostained with anti-vimentin and anti-glial fibrillary acidic protein (GFAP) antibodies according to supplier recommendations. The immunohistological examinations assisted the diagnosis of oligodendroglioma, astrocytoma, or mixed gliomas in the tumors.
Anti-angiogenic therapy
To test the effect of the VEGF receptor inhibitor SU-5416 (Sugen, San Francisco, CA), tumors were induced in rats as described above, which were initially imaged by T2-weighted MRI when the animals were 5 months of age. Animals with tumors with smaller than 0.35-mm diameter were randomly divided into control and treatment groups. Treated animals received 50 mg/kg of SU-5416 twice a week in a controlled release formulation. Control animals received the suspension diluent alone. Animals were generally imaged twice a week utilizing T2 weighting with either 0.5 or 1 mm thick slices with a TR/TE = 3,000/60. Tumor volumes were measured as described above. T1-weighted images with and without gadolinium contrast agent were acquired in selected animals during treatment with the SU-5614 compound as detailed in the figure legends.
Results
Development of ENU-induced tumors
Intracranial tumors induced by transplacental induction with ENU first became visible by MRI beginning at 4 months of age in the control animals. ENUinduced tumors appeared as a black T2-hypointense mass, frequently associated with a T2-hyperintense ring (white) surrounding the mass (Figure 1) . After a period of tumor growth (generally one or two months), alterations in the signal intensity of the T2 images were observable within many of the tumors ( Figure 2 , Month 2). These alterations had the appearance of a reticular network in the MRI's, which appear to correlate with the appearance of endothelial proliferation observed in histological sections of these tumors ( Figure 3 ). Additional data shows these reticular areas as developing vascular elements of the tumors. T1-weighted imaging with gadolinium contrast enhancement (Figures 4a,b) shows contrast enhancement of these areas, but not of the more hypointense areas, which are presumably tumor cells. Later still was the appearance of cysts within the tumor (Figure 2, Month 3) . Cyst development is consistent with an increase in vascular permeability, as evidenced by increased gadolinium contrast enhancement with T1 imaging (Figure 4a ). All tumors with cysts were found to be high-grade tumors, suggesting that cyst formation is a marker of progression of tumors in this model. These tumor masses could continue to increase in size for several months before any neurological deficits were observed.
Effect of dietary retinol on measurement of time to first tumor and tumor multiplicity
Dietary RP produced a significant delay in the time to first tumor (TTT) compared to ENU controls. shows that rats ingesting 150,000 IU/kg of feed of RP exhibited a shift in the TTT curve of approximately 1 month (Wilcoxon log rank test, P = 0.05). The effect of RP on delaying tumor formation is transitory, with the largest effect being observed during months 4 and 5. After this time greater than 75% of the animals in both groups had developed their first tumor.
Taking advantage of the repeated measures within each animal, the total number of tumors at each imaging session was determined by counting tumors in each contiguous serial slice. Figure 6a shows the average number of tumors in surviving animals each month. Commonly, tumor multiplicity is determined at a single time point at animal sacrifice when the total number of tumors is counted. Since imaging allows determination of tumor multiplicity without animal sacrifice, we were able to determine tumor multiplicity monthly for each animal. We also determined the rate of new tumor formation from the time of first tumor occurrence. Figure 6b , the rate of formation of the new tumors was analyzed using a generalized linear mixed model. The number of new tumors in each month is assumed to follow a Poisson distribution, based on an analysis of the residuals. A logarithmic link is used to relate the mean of this Poisson to a quadratic function of time for each treatment. The plot in Figure 6b shows the mean estimated rate of tumor formation for each treatment arm as a function of time from formation of the first tumor. The difference in the linear component of the rate of tumor formation between the ENU control group and RP treated animals was not significantly different (P = 0.89). There is some suggestion that the non-linear component of the rate of new tumor formation (i.e. the curve of the line) may be different between treatments (P = 0.04). However, there is limited data for RP treated animals having tumors for 4 months or longer that may influence the estimation of the curvature. Thus, RP appears to delay the time to occurrence for multiple tumors, but the rate of formation is unchanged.
Shown in
Effect of dietary retinol palmitate on tumor growth rates
Using repeated MRI measurements, we were able to quantify changes in tumor volumes over time. Figure 7 shows the changes in the first tumor volumes for animals in which the first apparent tumor was within the cerebrum, a location that is generally consistent with mixed glioma histology. Tumor growth rates showed mean doubling times of 0.487 ± 0.112 and 0.559 ± 0.153 months for ENU and ENU+RP treatments, respectively, a non-significant difference.
Tumor histology
A neuropathologist (MB) graded the tumors as low to high grades of malignancy using the criteria described by Zook et al. [26] . In the case of heterogeneous tumors, they were graded at the highest grade observed. Tumor histology of all tumors found at the end of the animal's life showed a mixture of low-to highgrades (Table 1) , consistent with previous observations in this brain tumor model. There appeared to be a large dichotomy in the tumor grading. Tumors that had progressed beyond the low-grade criteria had variable regions of high-grade morphology, thus there were no 'pure' intermediate grade tumors. Several of the Figure 7 . Measurement of tumor growth rates. Tumor volumes were quantified for animals in which the first tumor was found intracortically. Growth rates were determined for both control (A) and RP-treated (B) animals. The plots show the changes in tumor volume over time, with the curves shifted to adjust the intercepts of the curves to be normalized to 1 mm 3 . low-grade tumors were microtumors, which were not imaged by MRI. Of the tumors that were quantified for growth rates described above, with the exception of one lowgrade oligodendroglioma, all were high-grade mixed gliomas. These showed increased mitotic figures, approximately 50% with marked nuclear pleomorphism, and approximately 20% with undifferentiated small cell clones. High-grade tumors showed necrosis, marked endothelial proliferation and individual cell necrosis. Many tumors also appeared to have entrapped neurons as a part of the neoplasm. The mixed-gliomas displayed a variable proportion of oligodendrocytes to astrocytes as determined from immuno-histochemistry ( Figure 8 ).
Effect of dietary RP on survival
Although RP delayed time to first tumor formation (TTT), in this experiment dietary RP did not produce a survival advantage. Figure 9 shows the Kaplan-Meier survival curve for the two groups. Dietary supplementation of RP although suggestive, did not increase survival significantly over the ENU control group (P = 0.18, Wilcoxon test). Early increased survival by RP did not extend indefinitely as the survival curves merge towards the end of the experiment at 11-12 months. However, RP-treated animals developed a larger number of spinal cord tumors causing hind leg paralysis, these were confirmed at autopsy (6/12 animals with RP treatment vs. 3/12 animals for controls). The development of spinal cord tumors or other additional secondary tumors with increasing age may have altered the survival analysis.
Effect of anti-angiogenic therapy on tumor growth rates
We treated rats with small ENU induced tumors, in a second experiment, to examine the therapeutic potential for the anti-angiogenic drug SU-5416 in this model. Changes in tumor volumes for control (n = 3) and SU-5416 treated animals (n = 3) were determined at 4-7 day intervals ( Figure 10 ). Tumor growth in control animals was as described above in the RP experiment, with two of the three animals developing cysts within one of their tumors and subsequently sacrificed due to neurological impairment (Figure 10 upper left panel and Figure 11 ). Treatment with the drug SU-5416 resulted in reduced growth rates of tumors in two of three treated animals ( Figure 10 lower left and right panel and Figure 11 ) and possibly complete regression of a small tumor in the third (see the discussion section). MR images of the treated tumors showed little change in either size or imaging characteristics such as the development of, or increased amount of the reticular formations suggestive of vascularization. One of the three SU-5416 treated animals developed a tumor cyst suggesting evidence that SU-5416 may not delay the progression of these tumors. Histological analysis supports this observation (Figure 12 ). For example, in animal 2836 tumor growth was minimal, but the histology of the two tumors in this animal were both classified as high-grade mixed gliomas. These tumors lacked significant vascular proliferation and the remaining vessels were thin walled in contrast to control animals.
Discussion
Past studies, utilizing oncogenetic or chemically induced tumors, have been limited by their inability to determine the precise time and location of CNS tumor occurrence. Alternatively, survival analysis or time to neurological impairment has been used as a parameter in the evaluation of neurooncopreventative agents, but this is a crude endpoint providing little information about tumor incidence or growth. From previous studies, we recognized that testing agents for their preventive or therapeutic efficacy in models of spontaneous carcinogenesis would be difficult without the ability to detect tumor formation or growth, in addition to animal survival. As non-invasive imaging of brain tumors is becoming more common, MRI was used in order to obtain a more accurate determination of the number, incidence, and growth rate of the tumors. Initially applied to transplanted tumor animal models to measure growth, several groups have also used it to detect tumors produced by ENU exposure MRI [33] [34] [35] [36] .
This study confirmed the progressive growth of ENU-induced brain tumors in this model. It is well documented that ENU induces areas of increased proliferation that form microtumors by 60-90 days of age [44] [45] [46] [47] . The growth of these microtumors into macroscopic tumors occurs between 4 and 5 months of age, which correlates with the appearance of the lesion within the cerebrum apparent by T2-weighted MRI. These tumors can frequently be observed as small 0.5 mm (approximately 3-µl volume) although it is difficult to differentiate tumors at this size from large blood vessels or MRI artifacts. Tumors reaching 1-mm diameter are readily identifiable by T2 weighted MRI. The appearance of a hyper-intense ring on the T2 images at the periphery of the tumor suggests that this may be an area of increased water content, possibly caused by increased vascular permeability. VEGF has been shown to be expressed very early in the brain Figure 9 . Time to death. The Kaplan-Meier survival curve for the two groups is shown. No significant increase (Wilcoxon log rank test, P = 0.18) in survival due to RP treatment was detected. tumors induced by ENU [48, 49] . Increases in vascular permeability are thought to be associated with the angiogenic process and this is further supported by the size of the tumor (∼1-2 mm), which is within the range postulated for the development of vascular elements (the angiogenic switch [50] [51] [52] ). It has been shown that both microvessel density and VEGF levels are independent prognostic markers of survival in fibrillary low-grade astrocytoma in humans [53] . This finding led them to suggest that fibrillary diffuse lowgrade astrocytoma is composed of a spectrum of tumors with differing propensities to undergo malignant transformation that is at least partly based on their inherent angiogenic potential. A similar scenario can be envisioned for ENU-induced tumors in this model. ENU-induced tumors were found to increase in size throughout the animal's life. Although tumor volume is negatively linked with survival [26] , the size of the tumor is not a good predictor of survival, as several animals with extremely large tumors showed no neurological deficits and survived for extended periods (data not shown). Because of the rapid growth rate of the mixed gliomas, we believe that the majority of tumors imaged developed into mixed gliomas, which is supported by the histological and immuno-cytochemical results. The tumor growth analysis for the RP dietary treatment was limited to the first tumor to appear within the cerebrum by MR imaging. We observed that a majority of the macroscopic intracranial tumors induced in the Fisher-344 rat offspring were mixed gliomas thus suggesting a limitation of the potential variation in histological types We did not conduct an exhaustive search for early neoplastic proliferations or microtumors. The use of tumor diagnosis at the time of terminal sacrifice describes very little of the 'natural history' of these tumors and is of minimal significance except to reaffirm the finding that the tumors imaged were generally a homogenous population of mixed gliomas. We believe, based on the literature and our unpublished observations, that there is a strong correlation between the size of a tumor and its grade. Unfortunately, due to the limited number of animals in this pilot study, we were unable to perform interim sacrifices to correlate tumor size with grading. However, all of the large tumors that were imaged and graded as 'high grade' at sacrifice were derived from small tumors. Low-grade tumors were only observed as small tumors. The low number of anecdotal low-grade tumors are reflective of the time of sacrifice (late-stage) and may not be reflective of the tumor histology of the earlier occurring small tumors that progressed to be high-grade, malignant mixed gliomas.
This study, as does our previous one, supports that in the ENU model, retinoids may delay the onset of brain tumor formation, but do not appear to prevent it. This observation is similar to the effect of retinoids in delaying onset of ENU-induced leukemia in mice [54, 55] . Our observation that RP increases the latency period for macroscopic tumors is in conflict with an earlier report by Grubbs et al. [56] , where retinyl acetate, 13-cis-retinoic acid and all-trans-retinoic acid did not alter the incidence, number or latency period of the induced tumors. However, dosage and chemical form of the retinoid, strain of rat used and methodology used to detect initial tumor formation varied between the two experiments and may explain the discrepancy.
The lack of treatments with therapeutic efficacy for brain tumors has driven the continued search for novel therapies. Although the ENU-CNS tumor model has been known for over 30 years, there are relatively few reports of therapeutic trials try to inhibit the process of tumor induction or progression in rats. Particularly attractive are therapies that limit the growth or progression of the glioma by modulating the proliferative rate of either the tumor or the tumor's vasculature. Both chemopreventative and anti-angiogenic therapies have been proposed as methods for blocking tumor formation and growth. However, many of the chemopreventative agents are gaining recognition as potentially having anti-angiogenic properties. As described above, VEGF has been shown to be expressed very early in the brain tumors induced by ENU [48, 49] . All-trans retinoic acid (RA), 13-cis RA and all-trans retinol reduced VEGF secretion by human keratinocytes in primary cultures [57] . Reductions were observed at concentrations as low as 10 −10 M for all-trans RA, a level that is easily reached in vivo during retinoid treatment.
Increased cyclooxigenase (Cox) activity has also been reported to simulate angiogenesis [58] . The ability of NSAIDs (non-selective Cox 1 and 2 inhibitors) to exert a protective effect on the development of neural tumors [31] , suggests that Cox may play a role in brain tumor development as has been shown in colon cancer. Retinoids (RA, 13-cis-RA, and retinol acetate) have been shown to markedly suppress increases in amounts of Cox-2 and the production of PGE2 stimulated by phorbol myristate acetate (PMA) in human oral epithelial cells [59] . The authors also found that retinoids suppressed the induction of Cox-2 mRNA by PMA. Nuclear run-offs revealed increased rates of Cox-2 transcription after treatment with PMA; this effect was inhibited by all-trans-RA. Transient transfection experiments showed that PMA caused nearly a 2-fold increase in Cox-2 promoter activity, an effect that was suppressed by all-trans-RA [60] . Thus both inhibition of tumor growth and vascularization are potential mechanisms of action for RP in the ENU model.
It should be pointed out that previous studies with ENU-induced brain tumors have examined tumor incidence and multiplicity with either terminal or interim sacrifices. Sacrifices provide a 'snapshot in time' of tumor status in animals, and interim sacrifices to determine tumor incidence, this dramatically increases animal group size required for statistical validity, and requires serial histological sectioning for tumor detection. The detection of time of initial tumor formation (macroscopic), the development of multiple tumors, and serial measurements of growth rates have not been previously demonstrated for individual animals. Using the MRI approach, time-to-tumor incidence appears to be an especially sensitive early endpoint marker. The lack of a significant increase in the survival time by RP in this study is perplexing, especially in light of our previous study, which did find RP to increase survival time [37] . There are several possible explanations. First, the number of animals used in this pilot study was small. This limited the statistical power to determine survival differences, which was further limited by the censoring of animals (no reported death or autopsy) at the end of the study. Second, this study used Fisher-344 rats while our previous study used Sprague-Dawley rats. Both strains are susceptible to ENU-induced tumor formation, but the results of the effectiveness of RP in increasing survival may indicate a strain difference. Finally, and potentially the most important, was the alteration in the day of transplacental tumor induction from day 15 in the previous study to day 21 in the current study.
Although our intention was to maximize the number of tumors induced by ENU, we may also have unexpectedly altered the ratios and locations of observed CNS tumor types. We discovered a large number of spinal cord tumors at terminal sacrifice: 3/12 animals in the control and 6/12 animals in the RP treated group (each group had one animal censored from analysis due to lack of autopsy), a more frequent observation than in our previous study. Others have also observed this increased frequency of spinal cord tumors resulting from chemical induction late in the gestation period or postnatally [20, 61, 62] . The occurrence of rapidly growing spinal cord tumors in the rat is far more lethal due to the limited space available for tumor expansion in the spine. Thus, the lack of increased survival by the RP-treated animals is a complex problem, which further illustrates the difficulty in the interpretation of survival studies with this model.
We demonstrated the ability to measure the therapeutic interventional capability in the ENU model utilizing the anti-angiogenic drug SU-5416 in a small pilot study. SU-5416 has been previously shown to reduce the growth rate of an implanted high-grade glioma cell line [41] . In our experiment, SU-5416 inhibited tumor growth in each of the three animals treated. Two animal tumors were growth arrested, while a third animal's tumor appeared to have regressed, but we are unable to exclude that this was an artifact of the MRI or a large blood vessel since we were unable to obtain serial images in time of this tumor. Although SU-5416 was able to reduce the growth rate of tumors this compound appeared to not alter the presumed progression from lower to higher grades. Treatment with SU-5614 yielded small tumors with high-grade pathology, but with a marked absence of endothelial proliferation. The detection of hemaciderin with tumors treated with SU-5614 suggests that blood had leaked out of the vasculature during treatment. The significance of this observation needs to be examined both experimentally and clinically with anti-angiogenic treatments. Unfortunately, using MRI we are unable to accurately define tumor grade at the time of therapy initiation, so potentially the tumors were undergoing progression prior to therapy. Alternatively, inhibitors of angiogenesis such as SU-5416, while affecting tumor vasculature, do not alter the biological progression of the tumor cells within the tumor.
In conclusion, we have demonstrated that MRI images can provide meaningful information on tumor incidence, multiplicity, and growth rates in a spontaneously occurring brain tumor model. They provide early non-invasive endpoints, which can easily be correlated with the survival of the animal. The ability to perform repeated measurements to detect tumor occurrence and growth of the spontaneous tumors, reduces the number of animals needed for a study. In addition, the ENU-induced brain tumor model is a well-characterized animal model with initial low-grade tumors progressing to higher grades. We have demonstrated the feasibility of utilizing this model to test for either the chemopreventative or therapeutic efficacy of drugs on these spontaneous developing tumors before their progression to a high-grade tumor phenotype.
